Shots:

• TGA has provisionally approved the use of Moderna’s Spikevax (elasomeran) in individuals aged ≥12yrs. The decision follows the provisional approval granted by the TGA to Spikevax on Aug 09- 2021 for use in individuals aged ≥18yrs.
• Provisional approval for this group follows the data supporting the efficacy & safety of the vaccine. The recommended dose and dose interval is like that of the adult population – 2 full doses given 28 days apart
• The vaccine has received regulatory approval in this age group in several jurisdictions- including the UK- Canada- the EU- and Switzerland. TGA has secured 25M doses of Spikevax to diversify Australia's vaccine portfolio as well as provide access to a booster or variant vaccine

  | Ref: TGA | Image: Moderna